Andere Kunden interessierten sich auch für
![The Railroad Question A historical and practical treatise on railroads, and remedies for their abuses]( "The Railroad Question A historical and practical treatise on railroads, and remedies for their abuses")
The Railroad Question A historical and practical treatise on railroads, and remedies for their abuses19,90 €![The Land Question in Britain, 1750-1950]( "The Land Question in Britain, 1750-1950")
The Land Question in Britain, 1750-195081,99 €![Winston Churchill and the German Question in British Foreign Policy, 1918¿1922]( "Winston Churchill and the German Question in British Foreign Policy, 1918¿1922")
Winston Churchill and the German Question in British Foreign Policy, 1918¿192242,99 €![Growth market China: How European companies manage the delegation of power]( "Growth market China: How European companies manage the delegation of power")
Growth market China: How European companies manage the delegation of power54,99 €![Secrets of Question-Based Selling]( "Secrets of Question-Based Selling")
Secrets of Question-Based Selling17,99 €![The Taxation of Equity Derivatives and Structured Products]( "The Taxation of Equity Derivatives and Structured Products")
The Taxation of Equity Derivatives and Structured Products147,99 €![Launching New Products with a Direct Sales Force]( "Launching New Products with a Direct Sales Force")
Launching New Products with a Direct Sales Force49,90 €
In the past, high costs have been incurred in particular by the market launch of new medicinal products. To date, it was not necessary to demonstrate an additional therapeutic benefit. This changed with the Act on the Reform of the Market for Medicinal Products (AMNOG), which entered into force on the 1st of January 2011. It brought about a fundamental change in the balance of power on the pharmaceutical market.
This study therefore sets out to answer the following question: What impact does the early benefit assessment in the context of the AMNOG have on the stakeholders of the healthcare system? To answer this question, this survey first presents the theoretical foundations of the law, of the early benefit assessment and the bodies involved. It then takes stock of the decisions taken to date before describing the impact on the selected stakeholders.
This study therefore sets out to answer the following question: What impact does the early benefit assessment in the context of the AMNOG have on the stakeholders of the healthcare system? To answer this question, this survey first presents the theoretical foundations of the law, of the early benefit assessment and the bodies involved. It then takes stock of the decisions taken to date before describing the impact on the selected stakeholders.